via OTC PR WIRE — Puration, Inc. (USOTC:PURA) and Kali-Extracts (aka Kali, Inc.) (USOTC:KALY) today announced wrapping the Arnold Sports Festival in Johannesburg, South Africa featuring their EVERx CBD Sports Water. KALY is a PURA partner with a patented cannabis extraction process licensed to PURA and instrumental in the production of EVERx. PURA management has declared trade show a success with an initial order landing South Africa as the latest region where PURA now sells EVERx CBD Sports Water. PURA will publish a report on the trade show tomorrow to include details on the latest order coming out of the trade show.
EVERx was officially launched for the first time ever at the Arnold Classic in Columbus, Ohio in 2017, and now EVERx expands its presence at the Arnold Sports Festival events worldwide. EVERx is now an official sponsor of Jan Tana’s Body Painting Revolution featured globally at Arnold Sports Festival venues.
Jan Tana’s Bodypainting Revolution, A colorful and artistic event, returned to The Arnold in South Africa for the second straight year in 2019 after a spectacular recent production at the Arnold Classic Sports Festival in Columbus, Ohio.
The Arnold Sport Festival hosts multi-sport festivals on six-continents each year, including the Arnold Classic Africa, which takes place in Johannesburg, Gauteng, each May. The Arnold Sports Festival USA is held in Columbus, Ohio in March, followed by events in Melbourne, Australia, Brazil, Hong Kong and Spain. All events feature professional bodybuilding and related contests, amateur bodybuilding, strength and combat sports, a large health and fitness expo and youth events that vary from continent to continent.
For more information on Puration, visit http://www.purationinc.com
For more information on Jan Tana, visit https://www.jantana.com/
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.